Angela Rose Brannon

Title: Angela Rose Brannon: Innovator in Cancer Therapeutics

Introduction

Angela Rose Brannon is a distinguished inventor based in Cambridge, MA (US). She has made significant contributions to the field of cancer research, particularly in the development of biomarkers for evaluating therapeutic responses to rapamycin analogs. Her innovative work aims to enhance treatment strategies for cancer patients.

Latest Patents

Angela holds a patent titled "Biomarkers for response to rapamycin analogs." This invention focuses on utilizing biomarkers to assess the likelihood of an anti-cancer effect from rapamycin analogs in patients. The patent is grounded in experimental results that employ next-generation sequencing to analyze tumor specimens, revealing critical insights into tumor heterogeneity and the genetic factors influencing therapeutic responses. The invention provides assay methods and kits for detecting specific mutations that can guide treatment decisions for cancer patients.

Career Highlights

Angela is affiliated with the Memorial Sloan Kettering Cancer Center, where she continues her research and innovation in cancer therapeutics. Her work has the potential to significantly impact the way cancer is treated, particularly for patients with specific genetic backgrounds that affect their response to therapies.

Collaborations

Angela collaborates with notable colleagues, including James Hsieh and Michael Berger. These partnerships enhance her research efforts and contribute to the advancement of cancer treatment methodologies.

Conclusion

Angela Rose Brannon is a pioneering inventor whose work in cancer therapeutics is shaping the future of treatment options for patients. Her innovative approach to utilizing biomarkers represents a significant advancement in personalized medicine.